HC Wainwright Issues Positive Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings of ($1.24) per share for the quarter, up from their prior estimate of ($1.40). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.78) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($4.99) EPS, FY2027 earnings at ($5.66) EPS, FY2028 earnings at ($4.58) EPS, FY2029 earnings at ($1.13) EPS and FY2030 earnings at $1.29 EPS.

CRBP has been the subject of a number of other research reports. Oppenheimer decreased their target price on Corbus Pharmaceuticals from $57.00 to $54.00 and set an “outperform” rating for the company in a report on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $45.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday. Jefferies Financial Group decreased their target price on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen raised Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Corbus Pharmaceuticals Stock Up 6.3%

Corbus Pharmaceuticals stock opened at $12.15 on Thursday. Corbus Pharmaceuticals has a 52 week low of $6.72 and a 52 week high of $20.56. The company has a market capitalization of $215.49 million, a price-to-earnings ratio of -2.09 and a beta of 2.68. The stock has a 50-day moving average price of $9.77 and a 200 day moving average price of $9.66.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.03.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRBP. AQR Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals during the 1st quarter valued at about $573,000. Marshall Wace LLP purchased a new position in shares of Corbus Pharmaceuticals during the 2nd quarter valued at about $137,000. Bank of America Corp DE raised its stake in shares of Corbus Pharmaceuticals by 333.6% during the 2nd quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock valued at $496,000 after buying an additional 55,314 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Corbus Pharmaceuticals by 160.6% during the 3rd quarter. Aberdeen Group plc now owns 188,231 shares of the biopharmaceutical company’s stock valued at $2,381,000 after buying an additional 116,005 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Corbus Pharmaceuticals by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock valued at $7,742,000 after buying an additional 12,535 shares during the last quarter. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals News Roundup

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus reported Q1 2026 EPS of ($1.23), beating consensus by $0.03, which suggests results were slightly better than expected for the quarter.
• Positive Sentiment: The company said it reached broad FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, a meaningful regulatory step toward a registrational study this summer.
• Positive Sentiment: Corbus completed enrollment in the CANYON-1 obesity study for CRB-913, with topline 16-week data expected this summer, adding a near-term catalyst.
• Positive Sentiment: HC Wainwright and LifeSci Capital raised multiple earnings estimates across 2026-2030, reflecting improved expectations for the company’s long-term earnings trajectory.
• Positive Sentiment: Several brokerages maintained constructive views, including Guggenheim’s buy rating and Oppenheimer’s outperform rating, signaling continued analyst confidence. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Corbus will present at upcoming investor conferences in New York, which may increase visibility but does not by itself change fundamentals. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
• Negative Sentiment: Q1 net loss widened to about $23.0 million and operating expenses increased, underscoring that Corbus remains a high-burn clinical-stage biotech with no profits yet.
• Negative Sentiment: Oppenheimer cut its price target from $57 to $54, which is still bullish but may have tempered some enthusiasm.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.